Vincera Pharma Inc (VINC)

$0.07 -0.03 (-29.00%)
Market Cap 523,000.00
Revenue (ttm) 0.00
Net Income (ttm) -30.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,097,100
Avg Vol 1,143,596
Day's Range N/A - N/A
Shares Out 5.23M
Stochastic %K 5%
Beta 1.67
Analysts Strong Buy
Price Target $40.00

Latest News on VINC

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Apr 17, 2025, 4:45 PM EDT - 8 days ago

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

Apr 8, 2025, 4:05 PM EDT - 17 days ago

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

Mar 18, 2025, 8:52 AM EDT - 5 weeks ago

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Feb 28, 2025, 4:05 PM EST - 2 months ago

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Vincerx Pharma, Inc. Announces Reverse Stock Split

Jan 23, 2025, 4:05 PM EST - 3 months ago

Vincerx Pharma, Inc. Announces Reverse Stock Split

VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

Jan 6, 2025, 5:53 PM EST - 3 months ago

VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Dec 27, 2024, 4:05 PM EST - 4 months ago

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

Dec 4, 2024, 6:45 AM EST - 5 months ago

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates

Oct 8, 2024, 10:38 AM EDT - 7 months ago

Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

Oct 7, 2024, 4:05 PM EDT - 7 months ago

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:30 PM EDT - 9 months ago

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:15 PM EDT - 1 year ago

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Apr 26, 2024, 12:27 AM EDT - 1 year ago

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Apr 25, 2024, 4:01 PM EDT - 1 year ago

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Mar 29, 2024, 3:20 PM EDT - 1 year ago

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 5, 2024, 4:31 PM EST - 1 year ago

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Jan 7, 2024, 3:00 PM EST - 1 year ago

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Dec 10, 2023, 12:00 PM EST - 1 year ago

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 14, 2023, 7:00 AM EST - 1 year ago

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Vincerx Pharma To Present Three Posters at ASH 2023 in December

Nov 2, 2023, 9:10 AM EDT - 1 year ago

Vincerx Pharma To Present Three Posters at ASH 2023 in December

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

Sep 19, 2023, 7:00 AM EDT - 1 year ago

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

Sep 14, 2023, 7:00 AM EDT - 1 year ago

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

Vincerx Pharma Announces FDA Clearance of IND for VIP943

Aug 22, 2023, 7:30 AM EDT - 1 year ago

Vincerx Pharma Announces FDA Clearance of IND for VIP943

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 7, 2023, 9:25 AM EDT - 1 year ago

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 19, 2023, 9:05 AM EDT - 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 17, 2023, 1:35 PM EDT - 2 years ago

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Mar 28, 2023, 4:05 PM EDT - 2 years ago

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

Feb 6, 2023, 8:00 AM EST - 2 years ago

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

Dec 13, 2022, 9:29 AM EST - 2 years ago

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

Dec 12, 2022, 4:05 PM EST - 2 years ago

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Dec 11, 2022, 10:05 AM EST - 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 10, 2022, 4:05 PM EST - 2 years ago

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

Nov 3, 2022, 9:05 AM EDT - 2 years ago

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 11, 2022, 4:05 PM EDT - 2 years ago

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 3 years ago

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Jun 7, 2022, 2:19 PM EDT - 3 years ago

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Vincerx Pharma Provides Key Strategic Update

Jun 6, 2022, 4:05 PM EDT - 3 years ago

Vincerx Pharma Provides Key Strategic Update

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 12, 2022, 4:05 PM EDT - 3 years ago

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 8, 2022, 1:05 PM EDT - 3 years ago

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Mar 29, 2022, 8:00 AM EDT - 3 years ago

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 8, 2022, 4:35 PM EST - 3 years ago

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Feb 9, 2022, 8:00 AM EST - 3 years ago

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

Feb 3, 2022, 8:30 AM EST - 3 years ago

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Dec 17, 2021, 8:00 AM EST - 3 years ago

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome